BioMimetic Therapeutics Announces Highlights From 2012 Annual Meeting Of Stockholders
This press release contains forward-looking statements about our future
results of operations and financial position, product development
programs, business strategy, budgets, projected costs, plans and
objectives of management for future operations that are not historical
facts. The words “may,” “continue,” “estimate,” “intend,” “plan,”
“will,” “believe,” “project,” “expect,” “anticipate,” “optimistic” and
similar expressions may identify forward-looking statements, but the
absence of these words does not necessarily mean that a statement is not
forward-looking. There are many important factors that could cause
actual results to differ materially from those indicated in the
forward-looking statements, including factors related to: (i) the FDA
may not be satisfied with the Company’s amendment to its PMA and may
determine such PMA is not approvable or require additional clinical
trials; (ii) despite the Company’s future marketing and
commercialization efforts, Augment and Augmatrix may not achieve broad
market acceptance; and (iii) the EU regulatory authorities may determine
that the CE Mark for GEM 21S was improperly granted and may not approve
the CE Mark for Augment as a medical device. Further, BioMimetic’s
actual results and the timing and outcome of events may differ
materially from those expressed in or implied by the forward-looking
statements because of risks detailed in BioMimetic’s recent annual and
quarterly reports filed with the Securities and Exchange Commission,
including those factors discussed under the caption "Risk Factors" in
the Company’s Annual Report on Form 10-K filed with the SEC on March 13,
2012, which are incorporated in this press release by this reference.
Except as required by law, BioMimetic undertakes no responsibility for
updating the information contained in this press release beyond the
published date, whether as a result of new information, future events or
otherwise, and has no policy of doing so.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV